Tag Archives: Tyk2

Takeda Acquires Nimbus’ Tyk2 Autoimmune Program
December 13, 2022

Today we’re thrilled to announce the acquisition of Nimbus’ allosteric Tyk2 autoimmune program by Takeda for up to $6 billion in an upfront and future milestones. As a potential best-in-class asset in the significant new therapeutic category of selective Tyk2

Leave a comment

Nimbus Therapeutics Reaches Summit For Deal With Celgene
October 3, 2017

Today Nimbus and Celgene announced a significant partnership focused on autoimmune and inflammatory diseases. The alliance includes two pre-clinical autoimmune-focused programs in various stages of drug discovery. The most advanced program is a highly selective inhibitor of Tyk2, an immunokinase

Leave a comment